AU2021276264A1 - Engineered T cell receptors and methods of use - Google Patents

Engineered T cell receptors and methods of use Download PDF

Info

Publication number
AU2021276264A1
AU2021276264A1 AU2021276264A AU2021276264A AU2021276264A1 AU 2021276264 A1 AU2021276264 A1 AU 2021276264A1 AU 2021276264 A AU2021276264 A AU 2021276264A AU 2021276264 A AU2021276264 A AU 2021276264A AU 2021276264 A1 AU2021276264 A1 AU 2021276264A1
Authority
AU
Australia
Prior art keywords
tcr
seq
polypeptide
amino acid
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021276264A
Other languages
English (en)
Inventor
Ke Pan
Cassian Yee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2021276264A1 publication Critical patent/AU2021276264A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021276264A 2020-05-18 2021-05-17 Engineered T cell receptors and methods of use Pending AU2021276264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063026445P 2020-05-18 2020-05-18
US63/026,445 2020-05-18
PCT/US2021/032818 WO2021236548A1 (en) 2020-05-18 2021-05-17 Engineered t cell receptors and methods of use

Publications (1)

Publication Number Publication Date
AU2021276264A1 true AU2021276264A1 (en) 2022-12-22

Family

ID=78708026

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021276264A Pending AU2021276264A1 (en) 2020-05-18 2021-05-17 Engineered T cell receptors and methods of use

Country Status (8)

Country Link
US (1) US20230190812A1 (https=)
EP (1) EP4153618A4 (https=)
JP (1) JP7785696B2 (https=)
CN (1) CN116322715A (https=)
AU (1) AU2021276264A1 (https=)
CA (1) CA3183663A1 (https=)
TW (1) TWI907427B (https=)
WO (1) WO2021236548A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3236237A1 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
CN114149978B (zh) * 2022-02-09 2022-04-26 深圳博雅感知药业有限公司 制备car-t细胞的方法
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
JP2026505826A (ja) 2023-02-03 2026-02-18 ゼルナ・イミュノセラピー・アーエス 抗ｍａｇｅ－ａ４ ｔ細胞受容体
CN120924527B (zh) * 2025-10-16 2026-02-06 内蒙古科为博生物科技有限公司 一种内切葡聚糖酶突变体eg06、其编码基因及其产品与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173480A3 (en) * 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
CN102272153B (zh) * 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
KR20140039318A (ko) * 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
CN106103711A (zh) * 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
US11047011B2 (en) * 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
PL3440105T3 (pl) * 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
AU2018318303A1 (en) * 2017-08-18 2020-04-09 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
US20210061914A1 (en) * 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
EP3731861A1 (en) * 2017-12-29 2020-11-04 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof
EP3749753B1 (en) * 2018-02-09 2025-04-02 Immatics US, Inc. Methods for manufacturing t cells
DE102018108612A1 (de) * 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
EP3962939A4 (en) * 2019-05-03 2023-05-17 Gigamune, Inc. MODIFIED CELLS EXPRESSING ANTITUMOR T-LYMPHOCYTE RECEPTORS AND METHODS OF USING THEM

Also Published As

Publication number Publication date
EP4153618A1 (en) 2023-03-29
EP4153618A4 (en) 2024-06-26
JP7785696B2 (ja) 2025-12-15
TW202146438A (zh) 2021-12-16
JP2023528255A (ja) 2023-07-04
WO2021236548A1 (en) 2021-11-25
CN116322715A (zh) 2023-06-23
TWI907427B (zh) 2025-12-11
US20230190812A1 (en) 2023-06-22
CA3183663A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
JP7785696B2 (ja) 操作されたｔ細胞受容体および使用の方法
US20240009241A1 (en) Engineered t cell receptors targeting egfr antigens and methods of use
EP4423116A1 (en) Methods and compositions for treating glioblastoma
US20230227526A1 (en) Engineered t cell receptors and methods of use
US20230143031A1 (en) Engineered t cell receptors and methods of use
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
US20260007698A1 (en) Peptides and engineered t cell receptors targeting vcy antigen and methods of use
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
US20240009240A1 (en) Engineered t cell receptors targeting egfr antigens and methods of use
EP4422651A2 (en) Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
WO2025096983A1 (en) Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
WO2025101705A1 (en) Peptides and engineered t cell receptors targeting a melanoma antigen preferentially expressed in tumors antigen and methods of use
HK40120545A (en) Engineered t cell receptors targeting egfr antigens and methods of use
WO2026019786A1 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
EP4716699A2 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use